Citius PharmaceuticalsCTXR
13F holders, Q2 2025 (June 30)31holders +3
8new positions
5sold out
$1.59avg. 13F price*
At the end of Q2 2025, 31 institutions reported holding Citius Pharmaceuticals Inc. (CTXR) in their 13F filings, up 3 from Q1 2025. 8 opened new positions and 5 sold out. The largest holders were UBS Group AG ($307K), Cambridge Investment Research Advisors, Inc. ($292K) and Heights Capital Management, Inc. ($254K).
- Company
- Citius Pharmaceuticals Inc.
- CUSIP
- 17322U306
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 8 | $661K |
| Exits | 5 | $99K |
All 13F filers, Q1 2025 → Q2 2025: 556,353 shares bought and 263,089 shares sold, net +293,264 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 31 holders
| UBS Group AG | 0.00% | Add +187.0% | 192,927 | $307K |
| Cambridge Investment Research Advisors, Inc. | 0.00% | New | 183,534 | $292K |
| Heights Capital Management, Inc. | 0.08% | New | 159,898 | $254K |
| Vanguard Group Inc. | 0.00% | Reduce -68.9% | 80,103 | $127K |
| Geode Capital Management, LLC | 0.00% | Reduce -14.8% | 76,095 | $121K |
| BlackRock, Inc. | 0.00% | Reduce -3.3% | 69,851 | $111K |
| NewEdge Advisors, LLC | 0.00% | New | 25,000 | $40K |
| State Street Corp. | 0.00% | No change | 23,271 | $37K |
| XTX Topco Ltd | 0.00% | New | 20,146 | $32K |
| Arkadios Wealth Advisors | 0.00% | Add +100.0% | 20,000 | $32K |
| Bay Colony Advisory Group, Inc d/b/a Bay Colony Advisors | 0.00% | Add +17.9% | 16,500 | $26K |
| Northern Trust Corp. | 0.00% | Reduce -5.3% | 14,373 | $23K |
| Susquehanna International Group, LLP | 0.00% | New | 14,199 | $23K |
| Two Sigma Investments, LP | 0.00% | New | 12,874 | $20K |
| IFP Advisors, Inc | 0.00% | No change | 7,083 | $11K |
| Chelsea Counsel Co. | 0.00% | No change | 4,626 | $7K |
| SBI Securities Co., Ltd. | 0.00% | Add +77.2% | 4,018 | $6K |
| Osaic Holdings, Inc. | 0.00% | Add +10.5% | 1,687 | $3K |
| Group One Trading LLC | 0.00% | Reduce -80.6% | 649 | $1K |
| Luminist Capital LLC | 0.00% | No change | 435 | $827 |
| Bank of America Corp. | 0.00% | Add +454.4% | 377 | $599 |
| Raymond James Financial Inc. | 0.00% | New | 226 | $359 |
| Murphy & Mullick Capital Management Corp | 0.00% | No change | 160 | $254 |
| Princeton Global Asset Management LLC | 0.00% | No change | 160 | $254 |
| JPMorgan Chase & Co. | 0.00% | Reduce -11.8% | 120 | $191 |
| Smallwood Wealth Investment Management, LLC | 0.00% | No change | 120 | $190 |
| BNP Paribas Financial Markets | 0.00% | No change | 107 | $170 |
| Federation des caisses Desjardins du Quebec | 0.00% | No change | 80 | $127 |
| Morgan Stanley | 0.00% | No change | 60 | $95 |
| Larson Financial Group LLC | 0.00% | New | 45 | $72 |
| Fairscale Capital, LLC | 0.00% | No change | 42 | $58 |
"% of holder's portfolio" is CTXR's weight in each manager's 13F, not the share of Citius Pharmaceuticals Inc. the manager owns.